CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? Beloud

@fool.com · 46 minutes

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?

CRISPR Therapeutics has underperformed the broader market this year, with its stock rising only 8% compared to the 27% gain seen in the Nasdaq Biotechnology index. Despite high-profile backi...

Read more Fool.com